The Turkish CRC market
will grow at 4% annually between 2012-2017 and the number of CRC incident cases
will almost double between 2012-2022. Growing CRC population, entry of several
promising new agents and persistent use of branded agents are the key factors
driving this market. In this report, we examine the trends within Turkey’s CRC pharmaceutical
market, which is characterized by the wide use of KRAS testing,
universal healthcare, high patient shares for targeted therapies, the anticipated
launch of several emerging therapies, and Turkish government’s stringent price
Questions Answered in This Report:
Between 2012-2017, five new therapies are expected to enter
Turkey’s CRC market. Will these agents be entering existing drug classes or
will they feature novel mechanisms of action? How widely will these
agents be used in Turkey and will they pose considerable competition to the
current therapies? What are Turkish oncologists’ perceptions of the emerging
Pricing of therapies and reimbursement policies in the
public sector are major factors influencing expenditure on CRC treatments in Turkey.
How does the pricing of branded and generic agents used in treatment of CRC
vary between Turkey and the major markets? Which groups of Turkish
patients are eligible for government-reimbursed treatment of CRC? Which
targeted therapies are currently available to the Turkish patients and is it
likely that the patient shares of those agents will change substantially in the
next several years?
The Turkish CRC market will grow at 4% annually between
2012-2017. What was the size of the Turkish CRC market in 2012? How large
will the market be in 2017? What factors will drive growth in this market? What
factors will constrain it?
The number of incident cases of CRC in Turkey will nearly
double between 2012 and 2022. What was the number of incident cases of CRC
in Turkey in 2012? What was the stage distribution of diagnosed cases in 2012
and will it change by 2022? How many patients were diagnosed with colon cancer
and how many patients were diagnosed with rectal cancer?
Primary research: 73 oncologists surveyed across Turkey.
Separate in-depth interviews with 8 Turkish oncologists.
Epidemiology: Total incident cases of CRC in Turkey
over a ten-year period (2012-2022) by age, stage, gender, and localization.
Current therapies and medical practice: Reporting use
of brands and generics for the CRC treatments available in Turkey.
Pricing and reimbursement: Prices of CRC therapies in
Turkey versus other major markets and analysis of the impact of government
reimbursement on treatment trends.
Market forecast features: Our analysis evaluates
rates of CRC progression and rates of drug treatment with CRC therapies, across
all stages of the disease. We include a detailed forecast of current and
emerging therapies within platinum agents, antimetabolites, topoisomerase
inhibitors, angiogenesis inhibitors, and EGFR inhibitors from 2012 through 2017,
using a combination of historical trend analysis and an epidemiology-based,
bottom-up market model.